GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » European Biotech Acquisition Corp (NAS:EBACU) » Definitions » Operating Margin %

EBACU (European Biotech Acquisition) Operating Margin % : 0.00% (As of Dec. 2022)


View and export this data going back to 2021. Start your Free Trial

What is European Biotech Acquisition Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. European Biotech Acquisition's Operating Income for the three months ended in Dec. 2022 was $-1.17 Mil. European Biotech Acquisition's Revenue for the three months ended in Dec. 2022 was $0.00 Mil. Therefore, European Biotech Acquisition's Operating Margin % for the quarter that ended in Dec. 2022 was 0.00%.

The historical rank and industry rank for European Biotech Acquisition's Operating Margin % or its related term are showing as below:


EBACU's Operating Margin % is not ranked *
in the Diversified Financial Services industry.
Industry Median: 6.81
* Ranked among companies with meaningful Operating Margin % only.

European Biotech Acquisition's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

European Biotech Acquisition's Operating Income for the three months ended in Dec. 2022 was $-1.17 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2022 was $-2.82 Mil.


European Biotech Acquisition Operating Margin % Historical Data

The historical data trend for European Biotech Acquisition's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

European Biotech Acquisition Operating Margin % Chart

European Biotech Acquisition Annual Data
Trend Dec21 Dec22
Operating Margin %
- -

European Biotech Acquisition Quarterly Data
Jan21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22
Operating Margin % Get a 7-Day Free Trial - - - - -

Competitive Comparison of European Biotech Acquisition's Operating Margin %

For the Shell Companies subindustry, European Biotech Acquisition's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


European Biotech Acquisition's Operating Margin % Distribution in the Diversified Financial Services Industry

For the Diversified Financial Services industry and Financial Services sector, European Biotech Acquisition's Operating Margin % distribution charts can be found below:

* The bar in red indicates where European Biotech Acquisition's Operating Margin % falls into.


;
;

European Biotech Acquisition Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

European Biotech Acquisition's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-2.818 / 0
= %

European Biotech Acquisition's Operating Margin % for the quarter that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2022 ) / Revenue (Q: Dec. 2022 )
=-1.167 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


European Biotech Acquisition  (NAS:EBACU) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


European Biotech Acquisition Operating Margin % Related Terms

Thank you for viewing the detailed overview of European Biotech Acquisition's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


European Biotech Acquisition Business Description

Traded in Other Exchanges
N/A
Address
EPFL Innovation Park Building, Lausanne, CHE, 1015
European Biotech Acquisition Corp is a blank check company.
Executives
Mohammad Sohail Fazeli director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Martijn Kleijwegt director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Volkert H. Doeksen director RIOUWSTRAAT 10, THE HAGVE P7 2585HA
Fernandez De Araoz Eduardo Bravo officer: Chief Executive Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Koen Sintnicolaas officer: Chief Financial Officer JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Sponsor Ebac B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Van De Stolpe Onno director JOHANNES VERMEERPLEIN 9, AMSTERDAM, P7 1071 DV
Marcus Antonius Wegter director JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV
Lsp Management Group B.v. 10 percent owner JOHANNES VERMEERPLEIN 9, AMSTERDAM P7 1071 DV